PSMA-targeted peptide-MRI contrast agent for prostate cancer-specific MRI imaging

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K18082
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Hirosaki University
• Principal Investigator: Kojima Yuta 弘前大学, 医学部附属病院, 助教 (00792334)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: MRI / PSMA

Outline of Final Research Achievements

In this study, we aimed to establish a treatment efficacy monitoring method using a novel PSMA-binding peptide and gadolinium contrast agent as a low-exposure and versatile prostate cancer-specific imaging modality, and as a result, we discovered a PSMA-binding peptide (L7). Since there was a delay in the MRI monitoring of the therapeutic effect due to the problem of MRI facilities, we plan to continue the MRI monitoring of the anti-tumor effect using the L7-Gd complex after 2023. We plan to continue the study of MRI monitoring of the anti-tumor effect using the L7-Gd complex after 2023. The obtained research results will be published in a paper.

Free Research Field

泌尿器科学

Academic Significance and Societal Importance of the Research Achievements

本薬剤が前立腺癌に特異的に集積することから、学術的に前立腺癌の進展過程を検出できるツールとして意義があると考えられる。また前立腺癌の診断、ターゲット生検、転移巣の高精度検出など幅広い診療シーンで使用可能なモダリティとして期待され、さらに抗癌剤等を結合させることができれば、将来的には、前立腺癌特異的な治療が実現するため、より低侵襲な前立腺癌治療につながる社会的意義が非常に高いと考えられる。